Literature DB >> 16130931

Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma?

Bertrand Coiffier1.   

Abstract

Entities:  

Year:  2005        PMID： 16130931     DOI： 10.1038/ncponc0229

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


× No keyword cloud information.
  1 in total

1.  MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.

Authors:  Juan J Gu; Francisco J Hernandez-Ilizaliturri; Cory Mavis; Natalie M Czuczman; George Deeb; John Gibbs; Joseph J Skitzki; Ritesh Patil; Myron S Czuczman
Journal:  Anticancer Drugs       Date:  2013-11       Impact factor: 2.248
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.